The Quantellect read.As of Nov 19, 2026, 4 active firms cover Atrium Therapeutics, Inc. Common Stock: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $25.00 to $25.00, so the covering firms are broadly aligned. The average target of $25.00 sits 276% above the current $6.64. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.38 next quarter toward $-5.78 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$25.00
+276.2% upside
Average target across 4 active firms as of Nov 19, 2026 vs $6.65 current
Highest Target$25.00
Average Target$25.00
Lowest Target$25.00
Detailed analyst forecasts for RNA
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate RNA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RNA EPS & revenue forecast
EPS · NEXT QUARTER
$-1.38
Range $-1.48 – $-1.28 · 2 analysts
Next period, 2 analysts expect Atrium Therapeutics, Inc. Common Stock to earn $-1.38 a share (range $-1.48 – $-1.28), versus — a year earlier. Full-year consensus is $-3.17, growing to $-5.78 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $42.1M, rising to $1.6M next year.
Top analysts covering Atrium Therapeutics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RNA.
#1
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$68.00+923.3% to target
Overall win rate
45%
+ Follow
#2
Luca Issi
RBC Capital · Rank #76
Neutral
$72.00+983.5% to target
Overall win rate
49%
+ Follow
#3
Keay Nakae
Chardan Capital · Rank #130
Neutral
$72.00+983.5% to target
Overall win rate
41%
+ Follow
#4
Kristen Kluska
Cantor Fitzgerald · Rank #232
Buy
$25.00+276.2% to target
Overall win rate
38%
+ Follow
#5
Joseph Schwartz
Leerink Partners · Rank #242
Buy
$25.00+276.2% to target
Overall win rate
36%
+ Follow
RNA stock forecast FAQ
What is RNA's average 12-month price target?+
The 4 active firms with a live target average $25.00 for Atrium Therapeutics, Inc. Common Stock over the next 12 months, ranging from a $25.00 high to a $25.00 low, as of Nov 19, 2026.
Is RNA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover RNA?+
4 active firms have a recognized rating on Atrium Therapeutics, Inc. Common Stock as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RNA?+
Among analysts who currently cover RNA, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #73). Their current call is Buy with a $68.00 target.
What is Atrium Therapeutics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-1.38 per share (range $-1.48 – $-1.28) across 2 analysts. Full-year EPS is projected at $-3.17, rising to $-5.78 the following year.
How much revenue is Atrium Therapeutics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $42.1M, growing to $1.6M next year.
Have analysts been upgrading or downgrading RNA lately?+
As of Nov 19, 2026, 4 of 4 active firms rate RNA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RNA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.